Impact of TP53 mutations in Triple Negative Breast Cancer

Abstract

Identifying triple negative breast cancer (TNBC) patients expected to have poor outcomes provides an opportunity to enhance clinical management. We applied an Evolutionary Action Score to functionally characterize TP53 mutations (EAp53) in 96 TNBC patients and observed that EAp53 stratification may identify TP53 mutations associated with worse outcomes. These findings merit further exploration in larger TNBC cohorts and in patients treated with neoadjuvant chemotherapy regimens.

Fig. 1. Association of TP53 mutational status and clinical outcomes.

a Lollipop plot showing location and sequence of TP53 mutations in study cohort. Pink mutations denote those comprising the EAp53 1-69 group. b RFS Kaplan–Meier curves by tumor TP53 mutation status and location (log-rank test p = 0.162). c Kaplan–Meier curves by EAp53 category. d RFS Kaplan–Meier curves by pCR status (log-rank test p < 0.001). e RFS Kaplan–Meier curves by tumor TP53 mutation status for 43 patients who did not achieve a pCR (log-rank test p = 0.111).